NDAORALCAPSULE
Approved
Jun 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
29
Data completeness
6/8 — Strong
LITFULO (ritlecitinib) by Pfizer is inhibitor. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LITFULO (ritlecitinib) is an oral small-molecule JAK3/TEC kinase inhibitor approved by the FDA on June 23, 2023. It irreversibly blocks ATP binding to JAK3 and TEC family kinases, suppressing cytokine-induced STAT phosphorylation and immune receptor signaling. The specific indication and patient population are not detailed in available data.
$0.224MPart D
Peak15.0 years to LOEEarly-stage peak revenue profile with minimal Medicare claims suggests brand is still building market penetration; commercial team focus is on market development and physician adoption.
Mechanism of Action
inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Started Aug 2026
1 enrolled
Alopecia Areata
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Started Jul 2026
336 enrolled
Alopecia Areata
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Started Dec 2025
300 enrolled
Alopecia Areata
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Started Nov 2025
128 enrolled
Hidradenitis Suppurativa
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Started Oct 2025
200 enrolled
Chronic Spontaneous Urticaria
Worked on LITFULO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.